University of Bern, Inselspital, sitem-insel and CSL Research Acceleration Initiative

APPLICATION FORM

SUBMIT BY SEPT 30 2019

IMPORTANT: DO NOT INCLUDE ANY CONFIDENTIAL INFORMATION BELONGING TO A THIRD PARTY OR ALREADY COMMITTED TO A THIRD PARTY IN THIS APPLICATION FORM.

EXAMPLES OF SUCH CONFIDENTIAL INFORMATION THAT SHOULD NOT BE SHARED INCLUDE INFORMATION GENERATED WITH THIRD PARTIES THAT IS NOT IN THE PUBLIC DOMAIN, OR GENERATED THROUGH A GRANT WHERE A THIRD PARTY MAY HAVE PREFERENTIAL RIGHTS TO CONFIDENTIAL INFORMATION, INTELLECTUAL PROPERTY OR MATERIALS.

NOTWITHSTANDING THE FOREGOING, CSL BEHRING WILL TREAT ALL NON-PUBLICALLY AVAILABLE INFORMATION CONTAINED IN YOUR APPLICATION CONFIDENTIALLY.

For important additional information on eligibility, the application process and available support, please visit
https://www.cslbehring.ch/RAIBern

When complete, please send applications to samuel.hou@cslbehring.com with the subject line “CSL Research Acceleration Initiative Application”. Please also include data (tables, graphs) or cartoons as appropriate.

NOTE: ALL APPLICATIONS WILL BE REVIEWED AFTER THE SUBMISSION DEADLINE BY CSL

Please use the following form to submit your application and limit the content to the recommended word count.

1. DESCRIPTIVE RESEARCH TITLE (max 20 words)

Click here to insert text

2. THERAPEUTIC AREA (Select at least one)\*

|  |  |
| --- | --- |
| Immunology | Click here to insert text |
| Neurology | Click here to insert text |
| Haematology | Click here to insert text |
| Thrombosis | Click here to insert text |
| Transplant | Click here to insert text |
| Respiratory | Click here to insert text |
| Cardiovascular / Metabolic | Click here to insert text |

3. FOCUS AREA (IF APPLICABLE; select all that apply)\*

|  |  |
| --- | --- |
| Novel drug target | Click here to insert text |
| Clinical sample &/or clinical data collaborations | Click here to insert text |
| Novel platforms or technologies relevant to CSL Therapeutic Area or Modality | Click here to insert text |
| Novel delivery strategy or enhancement for biologic, gene or cell therapy | Click here to insert text |
| Biomarker(s) of disease | Click here to insert text |
| New use for CSL pipeline or on-market product (e.g. specialised assays, disease models, etc)  | Click here to insert text |

4. MODALITY (IF APPLICABLE, select ONE)\*

|  |  |
| --- | --- |
| Antibody | Click here to insert text |
| Protein therapeutic | Click here to insert text |
| Gene therapy | Click here to insert text |
| Cell therapy | Click here to insert text |
| Other (please specify) | Click here to insert text |

\*A minimum of one therapeutic area AND one focus area / one modality must be selected

5. NAME OF PRINCIPAL INVESTIGATOR leading this application

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Surname | Given Name | Position | Faculty / Institute | Email |
| 1 | Click here to insert text | Click here to insert text | Click here to insert text | Click here to insert text | Click here to insert text |

6. NAME OF OTHER INVESTIGATORS involved in this application (if applicable)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | Surname | Given Name | Position | Faculty / Institute | Email |
| 2 | Click here to insert text | Click here to insert text | Click here to insert text | Click here to insert text | Click here to insert text |
| 3 | Click here to insert text | Click here to insert text | Click here to insert text | Click here to insert text | Click here to insert text |

7. PROJECT SUMMARY (approx. 300 words)

Describe 1) your research hypothesis and the problem you are trying to solve; 2) the innovation you have developed that will enable the problem to be solved; 3) what you envisage the final product to be; and 4) the potential clinical or technological application (market) for your product, including who will ultimately use your product.

Click here to insert text

8. UNMET NEED (max 150 words)

Expand on the unmet medical need or technological gap that you are addressing.

Click here to insert text

9. COMPETITIVE LANDSCAPE (max 200 words)

Describe 1) the current standard of care and any other technologies in development that are attempting to address the same unmet needs as your technology; 2) the advantages of your technology/therapy over identified competitors and the current standard of care.

Click here to insert text

10. KEY FINDINGS (max 300 words)

Provide 1) details of any experiments or in vitro and in vivo data that you have generated to support your approach (include publication details if published); 2) if no data generated, provide rationale/evidence to support your hypothesis; 3) Briefly summarise any awarded funding or pending funding applications relevant to this proposal. Ensure you only include non-confidential information as defined above. Please contact your contact person at Unitectra or Martin Binggeli (binggeli@unitectra.ch) for guidance if uncertain.

Click here to insert text

11. PROOF OF CONCEPT RESEARCH PLAN (max 700 words)

Outline the high-level research plan you wish to address. Include key aims, experiments, milestones and timelines. How will you use CSL funding to advance your program and what outcomes will you achieve? As a guide, a total of up to CHF 400K will be awarded by CSL for up to 24 months. Ensure you only include non-confidential information. Please contact your contact person at Unitectra or Martin Binggeli (binggeli@unitectra.ch) for guidance if uncertain.

Click here to insert text

12. TEAM CAPABILITIES (max 300 words)

Describe the relevant capabilities and track record of the Applicants and include a summary of publications (top 5 most relevant publications of the Principal Investigator only).

Click here to insert text

13. INTELLECTUAL PROPERTY STATUS (max 150 words)

If applicable, briefly describe IP status (e.g. patents filed or granted) in collaboration with your contact person at Unitectra or Martin Binggeli (binggeli@unitectra.ch).

Click here to insert text